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Abstract. The ability of selective D- 1 agonist and antagon- 
ist drugs to alter motor deficits and locomotor activity 
was studied in MPTP-treated common marmosets. Both 
the D-2 agonist quinpirole and the mixed D-l/D-2 agonist 
apomorphine reversed the motor impairments and in- 
duced locomotor activity. The D-I antagonist SCH 23390 
and the D-2 antagonist raclopride given alone further 
reduced motor function in MPTP-treated animals. The 
actions of quinpirote were potently and completely inhib- 
ited by raclopride but only partially and inconsistently b
SCH 23390. In contrast, he effects of apomorphine were 
markedly but incompletely inhibited by both raclopride 
and SCH 23390. The D-1 agonist SKF 38393 alone 
caused a dose related reduction in motor activity. SKF 
38393 weakly and partially inhibited the improvements in 
motor function produced by quinpirole but had a more 
pronounced effect on apomorphine induced motor actiw 
ity. The induction of motor activity in MPTP treated 
common marmosets may separately involve both D-1 and 
D-2 receptors. Comparison with our previous data on the 
effect of the same drugs in normal common marmosets 
provides ome evidence for a breakdown of linkage be- 
tween D-t and D-2 systems following MPTP treatment. 
The actions of SKF 38393 in MPTP-treated common 
marmosets contrasts with its ability to induce behavioural 
activation and a facilitation of D-2 mediated behaviour in 
rodents. SKF 38393 may not be the compound with which 
to delineate the role of D-1 receptors in primates. 
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Brain dopamine receptors are families divided into D-l- 
like adenylate cyclase (AC) linked and D-2-1ike sites 
(Kebabian and Calne 1979). The latter are either negative- 
ly linked or not coupled to AC (Stoof and Kebabian 1981). 
In intact rodents distinct behaviours have been related to 
stimulation of D-1 and D-2 receptors. In addition, a corn- 
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plex functional interaction exists between D-t and D-2 
receptors. For example, D-1 receptor occupation by SKF 
38393 enhances tereotyped behaviour induced by the 
D-2 agonist RU 24213 (Pugh et al. 1985; Mashurano and 
Waddington 1986). Conversely, D-2 antagonist drugs can 
inhibit grooming induced by SKF 38393 (Murray and 
Waddington 1989). In addition, blockade of either D-I or 
D-2 receptors can allow the expression of novel behaviour 
through activation of the other class of dopamine recep- 
tors (Chandler et al. 1990). For example, treatment ofrats 
with the D-2 antagonist ulpiride allows the expression of 
vacuous chewing in rats by SKF 38393. 
In primates, imilar interactions between D-1 and D-2 
systems may not occur. In a preceding paper (Ltschmann 
et al. 1991) we reported on the effects of apomorphine and 
quinpirole alone and in combination with SKF 38393, 
SCH 23390 and the D-2 antagonist raclopride on locomo- 
tor activity and behaviour in normal common marmosets. 
The results indicated that although there were some simil- 
arities between the functional interaction between D-1 
and D-2 receptors in primates, there were significant dif- 
ferences indicative of a species difference. For example, 
SKF 38393 did not stimulate locomotor activity and 
inhibited that produced by quinpirole. 
Following the depletion of dopamine or the destruc- 
tion of dopamine neurones in rodents the linkage between 
D-t and D-2 receptor systems may be altered such that 
both D-1 and D-2 agonists now induce identical locomo- 
tor response but these are mediated independently 
through D-1 and D-2 receptor systems (Gershanik et at. 
1983; Arnt 1985; Arnt and Perregaard 1987; Sonsalla et al. 
1988). In addition, in mice depleted of endogeneous 
dopamine by treatment with reserpine and alpha-methyl- 
p-tyrosine (AMPT), D-2 agonists uch as bromocriptine 
(Jackson and Hashizume 1986) or quinpirole (Starr and 
Starr 1989) no longer induce locomotor activity unless 
there is concurrent administration f the D-1 agonist SKF 
38393. 
These results might suggest hat D-1 agonist drugs 
would themselves be useful in treating illnesses uch as 
Parkinson's disease or as adjuncts to therapy with D-2 
agonist compounds. However, in the MPTP-treated 
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primate, admin is t rat ion  of SKF  38393 had no  effect on 
motor  activity (Close et al. 1985; 1990; Nomoto  et al. 1985) 
and antagonized locomotor  st imulat ion induced by the 
D-2 agonist  quinpiro le (Nomoto  et al. 1988). In  other 
species of monkeys  treated with MPTP ,  SKF  38393 alone 
has been reported to have no effect and to inhib i t  D-2 
mediated motor  behaviours  (Barone et al. 1987; Boyce 
et al. 1990). 
It appears, therefore, that the relat ionship between 
D-1 and D-2 systems in pr imates may be different in 
animals  with nigrostr iatal  esions compared to events 
occurr ing in rodents. For  this reason, we have studied the 
effects of D- 1 and D-2 agonist  and antagonist  drugs in the 
MPTP  treated common marmoset  using the man ipu la -  
t ions previously employed in normal  animals  (L tschmann 
et al. 1991). 
Materials and methods 
Animals. Common marmosets (Callithrix jacchus) of either sex 
weighing 280-420 g, aged 2-10 years at the beginning of the study 
were used (n = 24). The animals were housed either in pairs or alone 
under standard conditions at a temperature of 27 ° ( ___ I°C) and 50% 
relative humidity using a 12 h light-dark cycle (light on from 6.00 to 
18.00 hours). The animals had free access to food pellets (Mazuri 
primate diet) and tap water, and in addition received a daily ration 
of fresh fruit and Mazuri marmoset j lly. During MPTP treatment 
and throughout the following weeks the animals were hand-fed with 
Mazuri marmoset jelly and fresh fruit puree until they were able to 
maintain themselves. Electrolyte, nutrient and fluid balance was 
maintained by SC infusion of an electrolyte, amino acid and vitamin 
solution (Duphalyte, Duphar, UK) when necessary. 
Rating of disability. When treated with MPTP and throughout the 
pharmacological experiments, the disability of the animals was 
scored using the following items: alertness (normal 0, reduced 1, 
sleepy 2); reaction to stimuli (normal 0, reduced 1, slow 2, absent 3), 
checking movements (present 0, reduced 1, absent 2); attention and 
eye movements (normal 0, abnormal 1); posture (normal 0, abnormal 
trunk 1, abnormal limbs + 1, abnormal tail + 1 or grossly abnor- 
mal 4); balance/coordination (normal 0, impaired 1, unstable 2, 
spontaneous falls 3), vocalisation (normal 0, reduced 1, absent 2), 
tremor (absent 0, present i). The maximum disability score possible 
was t8 whereas normal marmosets score 0. 
Measurement of locomotor activity. Locomotor activity was meas- 
ured simultaneously in four aluminium cages (50 x 60 x 70 cm) with 
stainless steel grid doors (50 x 70 cm) identical to the animals home 
cage but equipped with eight horizontally orientated s tsof infrared 
photocells. Across the cage three beams were located at floor level 
and one along each of the two perches. Other beams were directed 
from front-to-back of the cage at floor level and above ach perch. 
The number of light beam interruptions due to the animal's 
movements were accumulated in 10 rain intervals and recorded for 
120 min using a Commodore CBM 4032 computer. The animals 
were allowed to acclimatize to the test cage for a minimum of 30 rain 
prior to drug treatment. 
Behavioural observations. In parallel to the automated recording of 
locomotor activity the animals were observed through a one-way 
mirror. Immediately before drug treatments and throughout the 
experiment each animal was rated in 10 min intervals by an experi- 
enced observer using the disability scoring system. In addition, 
motor behaviour was rated qualitatively to determine the presence 
or absence of stereotypy, the degree of stimulation or inhibition, 
incidence of head twitches, wet dog shakes or grooming, oral move- 
ments and other obvious motor signs again in 10 min intervals for 
120 min after drug administration. I  addition a video recording of 
one animal in each treatment group was taken to allow post-hoc 
assessment of alterations in behaviour. 
Drug solutions. The following compounds were employed: MPTP 
(1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine hy rochloride; Re- 
search Biochemicals Inc., USA), SKF 38393 (2,3,4,5-tetrahydro-7, 
8-dihydroxy-l-phenyl)-lH-3-benzazepine hydrochloride, Research 
Biochemicals Inc., USA), SCH 23390 (1-chloro-2,3,4,5-tetrahydro- 
3-methyl-5-phenyl-lH-3-benzazepine-7-ol hemimaleate; Schering 
Corp., USA), apomorphine hydrochloride (Macfarlan Smith Ltd., 
UK), quinpirole (LY 171555; trans-(-)-4aR-4, a, 5,6,7,8, 8a,9-oc- 
tahydro-5-propyl-1H (or-2H)-pyrazolo(3,4g)quinoline mono- 
hydrochloride; Eli Lilly, USA), raclopride (S-(-)-3, 5-dichloro-N- 
[I-ethyl-2-pyrrolidinyl)methyl]-2-hydroxy-6-methoxy-benzamide; 
Astra, Sweden) and domperidone (Jansssen, Belgium). The solutions 
were prepared under sterile conditions. All compounds, except dom- 
peridone, were dissolved in sterile physiological saline and adminis- 
tered in a final volume of 1 ml/kg body weight. Domperidone was 
suspended in some drops of ethanol (70%) and diluted to volume 
(2 mt/kg body weight) with t0% sucrose/water solution and admin- 
istered by oral gavage. 
MPTP treatment. The animals were treated with MPTP in doses of 
2 mg/kg SC daily for up to 6 days since the response of individual 
animals differed markedly, variable dose regimes were applied to 
obtain stable motor deficits. The cumulative doses administered 
ranged between 8 and 12 mg/kg. Following MPTP treatment the 
animals recovered from acute effects over a period of some weeks. In 
the following months a further gradual recovery from the MPTP 
effects was observed. Before behavioural testing, 6 weeks to 
8 months after exposure to MPTP, the animals howed a marked 
reduction of basal locomotor activity, exhibiting slower and less 
coordinated movements, reduced checking movements of the head 
and eye blinks as well abnormal postures of some parts of the body. 
Drug treatments. Marmosets were randomly divided into groups of 
four and were subsequently reated with vehicle and the three doses 
of one test compound over the following weeks allowing a 1 week 
recovery period between doses. Individual animals were maximally 
employed in three such treatment groups with at least a 4 week 
period between experiments. A latin square design was used for the 
allocation of treatments within the groups. 
Dose response studies. Animals were pretreated with domperidone 
(2 mg/kg PO) 30 min prior to the subcutaneous (SC) administration 
of apomorphine (0.37, 0.75, 1.5 mg/kg or vehicle) or intraperitoneal 
(IP) administration of quinpirole (0.15, 0.3. 0.6 mg/kg or vehicle). 
Locomotor activity was recorded over the following 2 h period. The 
effects of SKF 38393 (1.25, 2.5, 5.0 mg/kg IP or vehicle), SCH 23390 
(1.25, 2.5, 5.0 mg/kg IP or vehicle) or raclopride (0.31, 1.25, 5.0 mg/kg 
IP or vehicle) were examined in an identical manner except hat 
pretreatment with domperidone was not necessary. In contrast o 
others (Close et al. 1990) and in agreement with our findings in 
normal common marmosets (Ltschmann et al. 1991) SKF 38393 did 
not induce nausea or vomitting in doses up to 5 mg/kg IP. 
Interaction studies. Animals were pretreated with domperidone 
(2 mg/kg PO) 15 min prior to the administration of SKF 38393, 
SCH 23390 (both 125, 2.5, 5.0 mg/kg or vehicle tP). A further 15 min 
later apomorphine (0.5 mg/kg SC) or quinpirole (0.5 mg/kg IP) were 
administered. Raclopride (0.31, 1.25, 5.0 mg/kg IP, or vehicle) was 
administered 15 min prior to apomorphine administration 
(0.5 mg/kg SC) or quinpirole (0.3 mg/kg IP). Monitoring of locomo- 
tor activity was started immediately following the last injection. 
Data analysis. The mean _+ SEM were calculated for time courses 
and accumulated locomotor counts of the different treatment 
groups. Statistical differences were calculated for accumulated loco- 
motor counts by the non-parametric Page test for ordered alternat- 
ives using exact distributions. 
Results 
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Effects of apomorphine and quinpirote on motor behaviour 
Administration of apomorphine (0.37-1.5 mg/kg SC) or 
quinpirole (0.15-0.6 mg/kg IP) caused a reversal of motor 
deficits and a dose dependent increase of locomotor activ- 
ity in MPTP-treated common marmosets (Figs 1 and 2). 
The effect of apomorphine was maximal within 10 min of 
administration and lasted for 80 min. At higher doses (0.75 
and 1.5 mg/kg SC) stereotyped movements ofthe limbs or 
the whole body were observed with an increase in poorly 
coordinated movements. Based on this observation a dose 
of 0.5 mg/kg SC was chosen for the subsequent drug 
interaction experiments. 
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Administration of quinpirole (0.15--0.60mg/kg IP) 
also produced a reversal of motor deficits and a sustained 
increase in motor activity which lasted throughout the 
observation period. In animals treated with quinpirole 
(0.6 mg/kg IP) pronounced stereotyped movements in the 
form of repetitive grasping or body waving occurred 
which reduced overall activity counts. A dose of 0.3 mg/kg 
quinpirole was chosen for subsequent interaction experi- 
ments. 
The effect of both apomorphine and quinpirole was to 
produce an increase in motor behaviour which took the 
form of very fast movements. Animals did not exhibit 
dyskinesia or dystonia. Increased grooming and oral 
movements were observed with quinpirole. Nausea and 
vomiting did not occur as animals were pretreated with 
domperidone. 
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Fig, IA, EL The effect of apomorphine on motor activity in MPTP-treated 
common marmosets. A Mean cumulative movement counts accumu- 
lated in 10 min intervals over 2 h ( + SEM, n = 4) of MPTP.treated 
common marmosets pretreated with domperidone (2mg/kg PO) 30 min 
prior to the subcutaneous administration ofvehicle ( -O- )  or 0.37 (-Q-),  
0.75 (-[3-) or 1.5 ( - I I - )  mg/kg apomorphine. Error bars for the lower 
doses of apomorphine are omitted for clarity but were in the same range 
as those shown for the vehicle and apomorphine 1,5 mg/kg SC treat- 
ment. B Mean cumulative movement counts accumulated over 2 h 
(+_ SEM, n = 4) for the data shown in A. Locomotor activity was 
increased by apomorphine (P < 0.05, Page test, ordered alternative: 
vehicle < 0.37 < 0.75 < 1.5 mg/kg apomorphine) 
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Statistical differences in disability scores were calculated com- 
paring scores prior to treatments to those at peak effects of treat- 
ments by the non-parametric Mann-Whitney U test. 
Fig. 2A, B. The effect of quinpirole on motor activity in MPTP-treated 
common marmosets. A Mean cumulative movement counts accumu- 
lated in 10 min intervals over 2 h ( 4- SEM, n = 4) of MPTP-treated 
common marmosets pretreated with domperidone (2mg/kg PO) 30 rain 
prior to the intral~eritoneal administration of vehicle ( -O- )  or 0.15 
(-O-),  0.3 (-£3-) or 0.6 ( - I I - )  mg/kg quinpirole. Error bars for the lower 
doses of quinpirole are omitted for clarity but were in the same range as 
those shown for the vehicle and quinpirole 0.6 mg/kg IP treatment. 
B Mean cumulative movement counts accumulated over 2 h ( + SEM, 
n = 4) for the data shown in A. Locomotor activity was increased by 
quinpirole (P < 0.01, Page test, ordered alternative: vehicle 
< 0.15 < 0.3 < 0.6 mg/kg quinpirole) 
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Effects of SCH 23390 and raclopride on motor behaviour 
Administration of SCH 23390 (1.25-5.0 mg/kg IP) caused 
a dose related decrease in locomotor activity in MPTP-  
treated common marmosets (Fig. 3A) and a significant 
increase in motor  disability (Table 1). The effect of SCH 
23390 took the form of an inhibition of locomotor activ- 
ity, reduced vigilance, catalepsy and complete akinesia in 
the highest dose tested (5 mg/kg IP). These effects were 
apparent within 10 min and lasted throughout he obser- 
vation period. 
Similarly, raclopride (0.31-5.0mg/kg IP) decreased 
locomotor activity (Fig. 3B) and enhanced motor  disabil- 
ity. The animals were cataleptic and akinetic for more 
than 120 min. Qualitatively there was no difference in the 
effects of SCH 23390 or raclopride although raclopride 
was more potent in augumenting disability (Table 1). 
Table 1. Disability scores prior to and at peak effect of various drug 
treatments 
Treatment Pre Post (70 min) 
SCH 23390 (5 mg/kg IP) 10.0 (3) 12.5 (2)* 
Raclopride (5 mg/kg IP) 10.5 (4) 14.0 (3)** 
SKF 38393 (5 mg/kg IP) 10.5 (3) t 1.5 (2) 
Quinpirole (0.3 mg/kg IP) 10.0 (3) 3.0 (1)* 
+ SCH 23390 (5 mg/kg IP) 9.0 (4) 5.0 (9) 
+ Raciopride (5 mg/kg IP) 6.5 (3) 15.5 (3)** 
+ SKF 38393 (20 mg/kg IP) 10.5 (5) 2.5 (5) 
Apomorphine (0.5 mg/kg SC) 9.5 (3) 2,5 (3)* 
+ SCH 23390 (5 mg/kg IP) 9.5 (4) 14.0 (1)** 
+ Raclopride (5 mg/kg IP) 11.0 (8) 12.5 (6) 
+ SKF 38393 (5 mg/kg IP) 9.5 (5) 7.0 (8) 
Behavioural scores are represented as the median scores of four 
animals per t eatment group with the range in parenthesis. 
Statistical differences between pre and post treatment values were 
calculated by the Mann-Witney U test (*: P < 0.05, **: P < 0.01) 
E 
1200 
1000 
800 
600 
400' 
200 
0 
vehicle 1.25 2.5 5.0 
SCH 23 390 [mg/kg i p ] 
E 
¢n 
o = 
(o 
1200 
1000 
800- 
600' 
400 
200 
vehicle 0.31 t .25 5.0 
Raclopride [mg/kg i p ] 
Fig. 3A, B. The effect of SCH 23390 or raclopride on motor activity in 
MPTP-treated common marmosets. A Mean cumulative movement 
counts accumulated over 2 h ( _ SEM, n = 4)of MPTP-treated com- 
mon marmosets following IP administration of vehicle, 1.25, 2.5 or 
5.0 mg/kg SCH 23390. Locomotor activity was decreased (P <0.05, 
Page test, ordered alternative: vehicle > 1.25 > 2.5 > 5.0 mg/kg SCH 
23 390). B Mean cumulative movement counts accumulated over 2 h 
( +_. SEM, n = 4) of MPTP-treated common marmosets following IP 
administration ofvehicle, 0.31, .25 or 5.0 mg/kg ractopride. Locomotor 
activity was decreased (P < 0.05, Page test, ordered alternative: vehicle 
> 0.31 > 1.25 > 5.0 mg/kg raclopride) 
Effects of SCH 23390 or raclopride on motor behaviour 
induced by quinpirole or apomorphine 
Quinpirole (0.3 mg/kg IP) caused an increase of locomo- 
tor activity (Fig. 2) and reversed motor  deficits with the 
appearance of some stereotyped behaviour. The disability 
scores were significantly reduced (Table 1). Administra- 
tion of SCH 23390 (1.25 -5.0 mg/kg IP) produced a slight 
but significant decrease in quinpirole-induced motor  ac- 
tivity (Fig. 4A); and attenuated the effect of quinpirole 
disability scores at the highest dose of SCH 23390 tested 
(5.0 mg/kg IP). Subjectively the movements were rated to 
be slower and less well coordinated when compared to 
quinpirole alone. In contrast, raclopride (0.31-5.0 mg/kg) 
completely antagonized the improvement in motor  func- 
tion produced by quinpirole (Fig. 4A), resulting in reduced 
vigi lance,complete akinesia and increased motor  disabil- 
ity (Tablel). 
The stimulation of locomotor activity and improve- 
ment of motor  deficits induced by apomorphine 
(0.5mg/kg SC) were reversed by both SCH 23390 
(1.25-5.0mg/kg IP) and raclopride (0~31-5.0 mg/kg IP) 
(Fig. 4B). Administration of both antagonists augmented 
the MPTP- induced disability even in the presence of 
apomorphine although the effect of raclopride was not 
statistically significant (Table 1). Convulsions were seen in 
two animals following 0.5 mg/kg apomorphine IP. These 
were readily antagonized by diazepam IM. Both animals 
were excluded from analysis and replaced by two animals 
which had no such a response following identical treat- 
ments. 
Effects of SKF 38393 on motor behaviour 
Administration of SKF  38393 (1.25-5.0 mg/kg IP) caused 
a dose related decrease in locomotor activity in MPTP-  
treated common marmosets (Fig. 5) and a tendency to an 
increase in motor  disability (Table 1). The effect of SKF  
38393 took the form of an inhibition of locomotor activ- 
ity, reduced vigilance in the highest dose tested (5 mg/kg 
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Fig, 4A, B. The effect of pretreatment with raclopride or SCH 23390 on 
locomotor activity induced by quinpirole or apomorphine in MPTP- 
treated common marmosets. Mean cumulative movement counts accu- 
mulated over2 h ( _+ SEM, n = 4) of MPTP-treated common marmosets 
pretreated with domperidone (2mg/kg PO) 15 min prior to administra- 
tion of vehicle or SCH 23390 (1.25, 2.5 or 5.0 mg/kg IP, hatched bars) or
raclopride (0.31, 1.25 and 5.0 mg/kg IP, #rey bars) and challenged with 
0.3 mg/kg IP quinpirole (A) or 0.5 mg/kg SC apomorphine (B) 15 min 
later. Locomotor stimulation induced by quinpirole was decreased 
by raclopride (P<0.01, Page test, ordered alternative: yehicle 
> 0.31 > 1.25 > 5.0 mg/kg raclopride) and Sch 23390 (P < 0.05, Page 
test, ordered alternative: vehicle > 1.25 > 2.5 > 5.0 mg/kg SCH 23 390). 
Locomotor stimulation induced by apomorphine was decreased by 
SCH 23390 (P<0.05, Page test, ordered alternative: vehicle 
> 1.25 > 2.5 > 5.0 mg/kg SCH 23 390) and raclopride (P < 0.01, Page 
test, ordered alternative: vehicle > 0.31 > 1.25 > 5.0mg/kg raclopride) 
IP). These effects were apparent within 10 min and lasted 
for up to 120 min. Animals did not exhibit stereotyped 
movements, purposeless chewing or other oral 
movements, dyskinesias, dystonia or increased grooming 
behaviour. No nausea or vomiting was observed. 
Effects of quinpirole or apomorphine in combination 
with SKF 38393 on motor behaviour 
Administration of quinpirole (0.3 mg/kg IP) reversed mo- 
tor deficits (Table 1) and increased locomotor activity, 
with some stereotypies (Fig. 2). Administration of SKF 
38393 (1,25-5 mg/kg IP) with quinpirole did not qualitat- 
ively or quantitatively alter the motor response to quin- 
pirole (Fig. 6A) although the animals were somewhat less 
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Fig. 5A, Bo The effect of SKF 38393 on motor activity in MPTP-treated 
common marmosets. A Mean cumulative movement counts accumu- 
lated in 10 rain intervals over 2 h ( + SEM, n = 4) of MPTP-treated 
common marmosets following intraperitoneal administration f vehicle 
(-O-) or 1.25 ( -0-) ,  2.5 (-El-) or 5.0 (- I I -)  mg/kg SKF 38393. Error 
bars for the lower doses of SKF 38393 are omitted for clarity but were in 
the same range as those shown for the vehicle and SKF 38 393 5.0 mg/kg 
IP treatment. B Mean cumulative movement counts accumulated over 
2h ( + SEM, n = 4) for the data shown in A. Locomotor activity was 
decreased by SKF 38393 (P < 0.01, Page test, ordered alternative: ve- 
hicle > 1.25 > 2.5 > 5.0 mg/kg SKF 38393) 
active. The incidence of stereotyped movements and
grooming behaviour was not altered by SKF 38393. Dys- 
tonia, dyskinesia or purposeless chewing were not ob- 
served. 
SKF 38393 when administered in higher doses 
(5.0-20.0 mg/kg IP) dose dependently antagonized the 
stimulation of locomotor activity induced by quinpirole 
(0.3 mg/kg IP) (Fig. 7). The effects of quinpirole on alert- 
ness and vigilance and overall on motor disability scores 
were not reversed by SKF 38393 (5-20 mg/kg) (Table 1). 
In contrast o the previous experiment, grooming and 
purposeless chewing were occasionally observed with 5.0 
and 10.0 mg/kg SKF 38393 IP but these did not occur at 
the highest dose tested. 
Administration of apomorphine (0.5 mg/kg IP) rever- 
sed motor deficits and induced an increase in locomotor 
activity and some stereotyped behaviour (Fig. 1), SKF 
38393 qualitatively altered the response to apomorphine 
in a way that the animals were less active (Fig. 6B); 
disability scores were only marginally reduced mainly due 
to a failure of apomorphine to reverse the impairment of 
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Fig. 6A, B, The effect of quinpirole or apomorphine in combination 
with SKF 38393 on motor activity in MPTP-treated common marmo- 
sets. A Mean cumulative movement counts accumulated over 2 h 
( __+ SEM, n = 4) of MPTP-treated common marmosets pretreated with 
domperidone (2 mg/kg PO) 30 rain prior to administration ofquinpirole 
(03 mg/q~g IP) alone or in combination with 1.25, 2.5 or 5.0 mg/kg IP. 
SKF 38393 administered 15 rain previously. Locomotor activity was not 
altered by SKF 38 393 administration. B Mean cumulative movement 
counts accumulated over 2 h ( + SEM, n = 4) of MPTP-treated com- 
mon marmosets pretreated with domperidone (2 mg/kg PO) 30 min 
prior to administration of apomorphine (0.5 mg/kg SC) alone or in 
combination with 1.25, 2.5 or 5.0 mg/kg IP SKF 38393 administered t5 
rain previously. Locomotor activity was decreased (P < 0.01, Page test, 
ordered alternative: vehicle > 1.25 > 2.5 > 5.0 mg/kg SKF 38393) 
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Fig. 7A, B. The effect of quinpirole in combination with SKF 38393 on 
motor activity in MPTP-treated common marmosets. A Mean cumulat- 
ive movement counts accumulated in 10 rain intervals over 2 h ( + SEM, 
n = 4) of MPTP-treated common marmosets pretreated with dom- 
peridone (2 mg/kg PO) 30 min prior to administration of quinpirole 
(0.3 mg/kg IP) alone ( -O- J  or in combination with 5.0 (-@-), I0.0 (-O-),  
or 20.0 ( - I I - )  mg/kg IP SKF 38393 administered 15 min previously. 
Error bars for the lower doses of SKF 38393 are omitted for clarity but 
were in the same range as those shown for the vehicle and SKF 38 393 
20.0 mg/kg IP treatment. B Mean cumulative movement counts accumu- 
lated over 2 h ( + SEM, n = 4) of MPTP-treated common marmosets 
pretreated with domperidone (2mg/kg PO) 30 rain prior to administra- 
tion of quinpirole (0.3 mg/kg IP) alone or in combination with 5.0, 10.0 
or 20.0 mg/kg IP SKF 38393 administered 15 rain previously. Loco- 
motor activity was decreased (P < 0.01, Page test, ordered alternative: 
vehicle > 5.0 > 10.0 > 20.0mg/kg SKF 38393 
coordination. The incidence of stereotyped movements as 
well as grooming behaviour was not altered by SKF 
38393. Dystonia, dyskinesia or purposeless chewing were 
not observed. 
Discussion 
At this time the MPTP-treated monkey appears to be the 
most suitable pharmacological model of Parkinson's dis- 
ease currently available. However, despite a vast literature 
on the function and interaction between D-1 and D-2 sites 
in rodents (for review see Clark and White 1987: LeWitt 
and Galloway 1987; Waddington and O'Boyle 1987), until 
now little is known of the role of these receptors in 
primates. 
Both the D-2 agonist quinpirole and the D- l /D-2 
agonist apomorphine reversed motor deficits and stimu- 
lated locomotor activity in MPTP-treated common mar- 
mosets. They also induced stereotyped behaviour when 
higher doses were administered. These effects are consist- 
ent with their effects in rats with 6-OHDA lesions, but 
contrary to what occurs in dopamine depleted mice where 
D-2 agonists alone do not stimulate motor activity with- 
out concurrent D-1 receptor stimulation. These data 
might suggest that in MPTP-treated marmoset there is 
sufficient endogenous dopamine remaining to produce 
D-1 tone. 
Although basal locomotor activity was low following 
MPTP treatment, both SCH 23390 and raclopride de- 
pressed it further: This suggests that either both D-1 and 
D-2 systems control motor activity or that SCH 23390 is 
able to reduce it through a D- l /D-2 receptor interaction. 
The latter seems less likely, since the effects of quinpirole 
were potently and completely inhibited by raclopride but 
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only partially and inconsistently by SCH 23390. This 
suggests that the locomotor effect produced by quinpirole 
is mediated by D-2 receptors, and that D-1 systems have 
relatively little ability to manipulate this D-2 mediated 
behaviour. However, D-1 systems appear to be able 
to influence locomotor activity induced by the mixed 
D-l/D-2 agonist apomorphine. Thus, the ability of both 
SCH 23390 and raclopride to potently but incompletely 
block apomorphine-induced motor activity supports the 
concept hat in MPTP-treated primates both D-1 and 
D-2 systems can i itiate locomotor activity but indepen- 
dently of one another. Such a conclusion isin good agree- 
ment with data generated from rodent studies. 
The concept of D-1 involvement in enhancing motor 
function is not supported by the actions of SKF 38393 in 
the MPTP-treated marmoset. In contrast to its effects in 
rodents, the D-1 agonist SKF 38393 did not stimulate 
locomotor activity in the MPTP-treated animals, but 
weakly inhibited movement and marginally increased the 
severity of the motor deficits. There was no evidence at 
any of the doses employed that SKF 38393 alone could 
induce novel behaviours or enhance the normal repertoire 
of behaviour of these animals, such aschecking or groom- 
ing which have been described in rats (Molloy and Wad- 
dington 1987). Similarly, in combination with quinpirole 
there was a dose-related inhibition of motor activity by 
SKF 38393 although this effect was partial and was only 
obvious at the higher doses used (10 and 20 mg/kg). These 
effects are in agreement with previous findings in primates 
(Nomoto et al. 1985; Brdard and Boucher 1989) but in 
contrast with the ability of SKF 38393 to facilitate D-2 
mediated motor behaviour in rodents (Braun and Chase 
1986) However, the weakness of the effect observed with 
SKF 38393 suggests that, if this is due to a D-1 mediated 
action, there is only minor control of D-2 initiated motor 
activity by D-1 systems in this model. In contrast, SKF 
38393 was more effective in inhibiting the actions of 
apomorphine which appear from the effects of SCH 23390 
to be partially mediated through the D-1 system. So, there 
is no clear explanation for the effect of SKF 38393 in 
primate species but these may relate to differences in the 
metabolism ofSKF 38393 in vivo leading to the formation 
ofa dopamine antagonist metabolite (Breese t al. 1990) in 
primates and humans but which does not occur in ro- 
dents. Alternatively, thedifference may relate to the par- 
tial agonist activity of SKF 38393 which could result in 
functional D-1 antagonist activity depending on the ex- 
tent of endogenous dopamine tone in marmosets follow- 
ing MPTP treatment. Indeed, a recent report demon- 
strates that the ability of SKF 38393 to stimulate aden- 
ylate cyclase in primate brain s lower than in rat tissue 
(Pitt et al. 1991). However, another partial D-1 agonist CY 
208-243 does produce a reversal of motor deficits and an 
increase in motor activity in MPTP treated common 
marmosets. This compound appears to be a typical D-1 
agonist in rodent studies indistinguishable from SKF 
38393 (Abbott et al. 199t and own observations). Clarifi- 
cation of the role of the D-1 receptor will have to await he 
examination ofa centrally active full D-1 agonist drug in 
primate species. 
The present experiments herefore only relate to the 
actions of SKF 38393 which was employed as the stan- 
Table 2. Qualitative comparison f effects upon locomotor activity 
in normal and MPTP-treated common marmosets 
Treatment Normal MPTP 
Raclopride 
SCH 23390 
SKF38393 
Quinpirole + + + 
+ Raclopride 
+ SCH 23390 
+ SKF 38393 
Apomorphine + + + 
+ Raclopride 
+ SCH 23390 0 
+ SKF 38393 0 
+++ 
/__ a 
+++ 
alnhibition following 5-20 mg/kg SKF 38393 IP 
Stimulation oflocomotor activity: + + + 
Complete inhibition of locomotor activity: 
Partial inhibition of locomotor activity: 
Weak inhibition of locomotor activity: 
No effect: 0 
dard D-1 agonist used to study the role of the D-1 recep- 
tor and its interaction with D-2 sites in rodents. Based on 
the effects of SKF 38393 and the other selective agents 
employed a number of tentative conclusions can be reach- 
ed on the actions of D-1 and D-2 drugs in MPTP-treated 
marmosets compared to he rat. First, D-2 agonist drugs 
alone are capable of stimulating motor function without 
the need for enhanced D-1 receptor tone. Second, the 
administration f SKF 38393 neither led to the expression 
of novel D-1 mediated behaviour, or to the facilitation f 
D-2 mediated behaviour. Finally, there was some evidence 
of separate involvement of D-1 and D-2 systems in the 
production of motor behaviours based on the differential 
ability of SCH 23390 and raclopride to inhibit quinpirole 
and apomorphine mediated motor activation. 
A further important comparison to make is the differ- 
ences in drug response in the normal marmoset compared 
to MPTP-treated animals (see Table 2). In normal mar- 
mosets both quinpirole and apomorphine stimulate mo- 
tor activity but there was a major difference in the re- 
sponse to antagonists compared to MPTP-treated ani- 
mals. In normal marmosets he effect of quinpirole was 
markedly reduced by raclopride and less so by SCH 23390 
but this latter effect was more consistent han in 
MPTP-treated animals. In addition, in normal marmosets 
the effects of apomorphine were again inhibited by rac- 
lopride but, unlike the MPTP-treated animals, not by 
SCH 23390. These data would suggest that in the normal 
animals locomotor responses are largely mediated by D-2 
systems but that there is some evidence for linkage be- 
tween these receptor systems. Further, in normal marmo- 
sets, SKF 38393 again inhibited motor function but it is 
considerably more potent in inhibiting the actions of 
quinpirole than in MPTP-treated animals again suggest- 
ing some form of linkage. 
The conclusion from our studies in both normal and 
MPTP-treated animals is that the nature of the relation- 
ship between D-1 and D-2 systems in marmosets is differ- 
ent from that occurring in rodents. However, it is the 
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pr imate model  which appears predictive of drug action in 
man since SKF  38393 did not improve motor  symptoms 
in Parkinson's disease when administered alone or in 
conjunction with L-dopa (Braun et al. 1987). 
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